Why IMU is a multi multi bagger, page-458

Dear all,

Hello from Leslie Chong

In exciting news released over the weekend, our Chief Medical Officer Dr Rita Laeufle and City of Hope’s DrYanghee Woo delivered outstanding presentations on our products at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).

Dr Laeufle presented on our HER-Vaxx cancer immunotherapy program (click here for a copy and click here for her oral presentation), while Dr Woo presented on our CF33 oncolytic virus program (click here). City of Hope’s Dr Woo serves as Associate Clinical Professor in the Department of Surgery, as well as Director of Gastroenterology Minimally Invasive Therapy Program.

The AACR presentation highlighted the following new data;

• Treatment with HER-Vaxx clearly demonstrates that all patients develop high levels of HER2-specific antibodies early in the treatment protocol.
• Analysis of the antibody data reveals high levels are maintained during the treatment and maintenance phases, with only minimal booster injections of HER-Vaxx required to maintain the high levels.
• The constant and high HER2 antibody levels correlate with the early separation of the Kaplan Meier (KM) Curves for overall survival (OS) and progression free survival (PFS) clinical trial endpoints. The Kaplan Meier Curve provides a recognised statistical estimation of the survival function which visually represents the probability of an event occurring for each treatment arm at a respective time interval.
• Overall, this interim data is suggestive that the treatment is effective and well tolerated with an overall survival benefit that is superior to chemotherapy alone.

Final tumourresponse, correlation of antibodies with tumour response, and final PFS and OSdata is expected to read out in 2021.

Dr Woo’s team engineered CF33-hNIS-antiPDL1, a uniquechimeric orthopoxvirus, which shows robust preclinical activity againstmany solid tumors and inherent strong anti-cancer activity againstpancreatic ductal adenocarcinoma (PDAC). The team investigatedCF33-hNIS-antiPDL1 for its ability to track and kill distant peritoneal metastasesafter local virus administration invivo.

I am personally very excited about the transformational opportunities we are developing. I encourage you to continue to follow our progress.

As always, many thanks for your enduring support.

Warmest,
Leslie